THE INTERNATIONAL JOURNAL OF
CLINICAL PRACTICE WILEY

Comparison of rapid antibody test and thorax computed tomography results in patients who underwent RT-PCR with the pre-diagnosis of COVID-19

Ilker Kızıloglu[1] | Aslı Sener[2] [iD] | Neslihan Siliv[2]

[1]Department of Emergency Medicine, Izmir Dr. Suat Seren Chest Diseases and Surgeries Training and Research Hospital, Izmir, Turkey

[2]Department of Emergency Medicine, Bakırcay University, Izmır Training and Research Hospital, Izmir, Turkey

Correspondence
Aslı Sener, Department of Emergency Medicine, Bakırcay University, Izmır Training and Research Hospital, Izmir 61750, Turkey.
Email: dr.asli_capaci@hotmail.com

Abstract

Introduction: In this study, it is planned to compare the real-time reverse transcription-polymerase chain reaction (RT-PCR) test, which is the gold standard in the diagnosis of COVID-19, with thorax computed tomography (CT) and rapid antibody test results.

Methods: Patients who were admitted to the emergency service of İzmir Çiğli Training and Research Hospital between 01.04.2020 and 31.05.2020 and who were suspected of having COVID-19 infection were included in the study. The medical records of the patients were retrospectively analysed through the hospital data processing database. Age, gender, hospitalisation, status of home quarantine, real-time RT-PCR, thorax CT and rapid antibody test results of the patients were examined. The relationship between RT-PCR, thorax CT and rapid antibody test results was compared statistically.

Results: A total of 181 patients, 115 (63.5%) male and 66 (36.5%) female, with an average age of 56.4 ± 18.06 years were included in the study. The nasopharyngeal swab PCR result obtained at the first admission of the patients to the emergency department was positive in 71 (39.2%) patients. Rapid antibody tests performed at hospital admission were positive in 57 (31.5%) patients. Thorax CT was performed in 173 (95.6%) patients who applied to the emergency department, and 112 (64.7%) of them had findings that could be compatible with COVID-19. According to the thorax CT findings in patients, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for detecting COVID-19 infection were, respectively, 76.1%, 43.1%, 48.2% and 72.1% (κ: 0.176, $P < .001$). According to the rapid antibody test results, sensitivity, specificity, PPV and NPV for detecting COVID-19 infection were 57.5%, 85.5%, 71.9% and 75.8%, respectively (κ: 0.448, $P < .001$). In our study, the mortality rate for COVID-19 was found to be 2.8%.

Conclusion: Rapid antibody test and thorax CT examinations were found to have low diagnostic value in patients who admitted to the emergency department of our hospital and whose first RT-PCR SARS-CoV-2 test was positive. Studies involving larger patient groups are needed for their use alone in diagnosis and screening.

1 | INTRODUCTION

In December 2019, a series of 41 severe viral pneumonia cases were reported in Wuhan city, Hubei Province, China, whose cause could not be identified.[1] Subsequent full genome sequencing and phylogenic analysis showed that SARS-CoV-2 belongs to the beta-coronavirus 2b lineage, which belongs to the same group as severe acute respiratory syndrome coronavirus (SARS CoV), a highly virulent pathogen in humans.[2,3] SARS-CoV-2 infection (COVID-19) was reported as a global public health emergency by the World Health Organization (WHO) in January 2020 and was declared a pandemic on March 11.[4,5]

The disease is transmitted by inhalation or contact with infected droplets, and the incubation period varies between 2 and 14 days. Symptoms are usually fever, cough, sore throat and dyspnoea. Symptoms are mild in most of the asymptomatic cases. However, in some patients (usually the elderly and those with co-morbidities), it can progress to pneumonia, acute respiratory distress syndrome and multiple organ dysfunction. It is estimated that the case mortality rate varies between 2% and 3%.[6] However, most people infected with SARS-CoV-2 do not have symptoms.[7,8] The potential for patients with no symptoms to spread COVID-19; it confirms the importance of early diagnosis, monitoring and isolation.

Accurate and rapid diagnosis of COVID-19 infection is very important to provide appropriate medical support to patients and to prevent disease spread by quarantine. The current recommendation for the diagnosis of active infection is to detect viral RNA from respiratory tract samples by real-time reverse transcription-polymerase chain reaction (RT-PCR).[9-12] RT-PCR test for COVID-19 is thought to have high specificity, but its sensitivity has been reported to be as low as 59%–71%.[13,14]

Alternative protocols with similar sensitivity were needed in SARS-CoV-2 screening due to the increasing rapidity of the COVID-19 pandemic, the difficulty of detecting asymptomatic cases, low sensitivity and time-consuming results of the RT-PCR test and the inability of thorax computed tomography (CT).[15-18] Recently, test methods have been developed for the rapid detection of combined SARS-CoV-2 IgG and IgM antibodies in human serum/plasma.[19] In our study, we aimed to evaluate the results of simultaneous thorax CT and ELISA-based IgM/IgG tests in COVID-19 patients diagnosed with RT-PCR in our emergency department and to demonstrate the value of serological tests in the diagnosis of COVID-19.

2 | MATERIAL AND METHODS

Among the patients aged 18 and over who applied to the emergency department with suspicion of COVID-19 between 01.04.2020 and 31.05.2020, the patients whose COVID-19 diagnostic code (U07.3) was entered according to the ICD-10 classification were included in the study. The medical records of the patients were retrospectively examined through the hospital data processing database. Patients

What's known

- Accurate and rapid diagnosis of COVID-19 infection is very important to provide appropriate medical support to patients and to prevent disease spread by quarantine.
- The current recommendation for the diagnosis of active infection is to detect viral RNA from respiratory tract samples by real-time reverse transcription-polymerase chain reaction (RT-PCR).
- Thorax computed tomography (CT) is important for the diagnosis of COVID-19 patients as well.

What's new

- The rapid antibody test COVID-19 used for evaluation gives a qualitative IgG/IgM result to reveal a current or past SARS-CoV-2 infection.
- Rapid antibody test is as useful for the diagnosis of COVID-19 as RT-PCR and thorax CT.

Review criteria

- Among the patients aged 18 and over who applied to the emergency department with suspicion of COVID-19 between 01.04.2020 and 31.05.2020, the patients whose COVID-19 diagnostic code (U07.3) was entered according to the ICD-10 classification were included in the study.
- The medical records of the patients were retrospectively examined through the hospital data processing database.

Message for the clinic

- Rapid antibody test can be useful for the diagnosis of COVID-19 in minutes.

younger than 18 years old, patients for whom the COVID-19 diagnosis code was not entered and those whose any of RT-PCR, thorax CT or rapid antibody tests were absent were excluded from the study.

A verified COVID-19 case was identified based on Coronavirus Pandemic Outbreak Management Guide published by the Republic of Turkey Ministry of Health the Science Board National Healthcare Commission. According to this guideline, the gold standard in the diagnosis of COVID-19 was considered to be RT-PCR positivity in nasopharyngeal swab (NS), sputum or endotracheal aspirates. Disease onset date, clinical classification, RT-PCR test results during the hospitalisation period and personal demographic information were obtained from the clinical records.

This study was reviewed and approved by the Bakırçay University Medical Ethics Committee. Written and verbal consents were obtained from all participants in the study.

2.1 | RT-PCR

Reverse transcription-polymerase chain reaction analysis was performed on materials obtained by NS from patients admitted to the emergency department. A one-step real-time RT-PCR test targeting the nucleocapsid gene and the open reading frame 1 ab gene was performed with 5 µL of a total nucleic acid according to the manufacturer's instructions.

2.2 | Rapid antibody test

The rapid antibody test (Bioeasy COVID-19 Coronavirus IgG/IgM GICA Rapid Test Kit©) used for evaluation gives a qualitative IgG/IgM result to reveal a current or past SARS-CoV-2 infection.[20] This test has been approved by the Ministry of Health for use in detecting antibody formation in risk groups in the community, healthcare workers and recovered patients. There are rapid antibody tests used for COVID-19 and produced by different companies. In head-to-head studies conducted with these tests, Bioeasy kits have been reported to have 91%–95% sensitivity levels (κ: 0.8, $P < .001$).[20] The rapid antibody test gives results in as little as 30 minutes. The serum sample taken for the test is dropped onto the cassette of the rapid test kit, and the presence of antibody is qualitatively shown in 15 minutes.

2.3 | Thorax CT protocol

CT imaging was performed in the supine position with raised arms and at the end of inspiration. Two radiologists experienced in the field of thorax CT reviewed the thin-section and thick-section CT images, respectively, and the decision was made. Radiologists have identified the dominant appearances on CT images: ground glass density, crazy-paving pattern, consolidation and other findings.

All thorax CT images were classified as normal, non-COVID lung findings, compatible with low probability COVID-19, intermediate probability COVID-19 and high probability-definite COVID-19 as previously defined.[13,21]

2.4 | Statistical method

SPSS 26.0 (IBM Corporation, Armonk, New York, USA) program was used in the analysis of variables. The compliance of non-parametric variables to normal distribution was evaluated using the Shapiro–Wilk Francia test. The Mann–Whitney U test was used together with Monte Carlo simulation results in comparing the two independent groups according to quantitative data. In the comparison of categorical variables, the Pearson χ^2 test, Fisher exact test and Monte Carlo simulation technique were tested and column ratios were compared and expressed according to the Benjamini–Hochberg corrected p-value results. Odds ratio was used with 95% confidence intervals to show how many times more risky those with a risk factor were

compared with those who did not. Sensitivity and specificity ratios for the relationship between the classification separated by the cut-off value calculated according to the variables of the groups and the actual classification were expressed by receiver operating curve (ROC) analysis. Kappa statistics were used to evaluate the correlation between PCR and rapid antibody test and CT methods. Quantitative variables were expressed as mean ± standard deviation and median (minimum/maximum) in the tables, whereas categorical variables were shown as n (%). Variables were examined at a 95% confidence level, and a p-value of less than 0.05 was considered significant.

3 | RESULTS

A total of 181 patients, 115 (63.5%) male and 66 (36.5%) female, with a mean age of 56.4 ± 18.06 years were included in our study, and 71 (39.2%) of the patients were diagnosed with COVID-19 confirmed by positive PCR. The demographic findings of the patients are summarised in Table 1.

Chest CT was performed in 173 (95.6%) of the patients, and findings that may be compatible with COVID-19 were found in 112 (64.7%). Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in the diagnosis of COVID-19 infection based on thorax CT findings were 76.1%, 43.1%, 48.2% and 72.1%, respectively (κ coefficient: 0.176, $P < .001$). In addition, in patients aged ≤57, sensitivity, specificity, PPV and NPV values of thorax CT positivity in detecting PCR positivity were 69.6%, 71.1%, 74.4% and 65.9%, respectively (κ coefficient: 0.403, $P < .001$) (Table 2).

The rapid antibody test performed during hospital admission was positive in 57 (31.5%) patients. The COVID-19 PCR positivity status of the patients was compared with the rapid antibody test findings. According to the rapid antibody test results, the sensitivity, specificity, PPV and NPV in detecting COVID-19 infection were 57.5%, 85.5%, 71.9% and 75.8%, respectively (κ: 0.448, $P < .001$) (Table 3).

Whereas the rate of hospitalisation of patients with positive COVID-19 PCR was higher, the rate of intensive care admission was lower than other patients. However, four (5.6%) of the patients with positive PCR were followed up as intubated in the intensive care unit. In our study, the mortality rate for COVID-19 was found to be 2.8%.

4 | DISCUSSION

Two main conclusions have been reached in our study. The sensitivity and specificity levels of rapid antibody tests in detecting COVID-19 cases confirmed by RT-PCR in the emergency department are 57.5% and 85.5%, respectively. In addition, thorax CT sensitivity and specificity were determined as 76.1% and 43.1%, respectively.

Regardless of whether people with COVID-19 infection are symptomatic or asymptomatic, early and accurate diagnosis is important for treating patients and reducing the rate of disease

TABLE 1 Demographic characteristics and clinical findings of the patients

	Mean ± SD	Median (min/max)
Age	56.54 ± 18.06	58 (18/93)
	n	%
Gender		
Female	66	36.5%
Male	115	63.5%
PCR		
Negative	110	60.8%
Positive	71	39.2%
Rapid antibody test		
Negative	124	68.5%
Positive	57	31.5%
Thorax CT		
No	8	4.4%
Yes	173	95.6%
CT finding		
Another diagnosis	10	5.8%
COVID-19	112	64.7%
Normal	51	29.5%
Need for MV		
No	159	87.8%
Yes	22	12.2%
Clinical management and follow-up		
Home isolation	36	19.9%
Exitus	13	7.2%
Hospitalisation	132	72.9%
Co-morbidity		
Absent	85	47.0%
Present	96	53.0%

Abbreviations: CT, computed tomography; max, maximum; min, minimum; MV, mechanical ventilator; SD, standard deviation.

spread. Molecular and serological tests were previously compared during the SARS-CoV-1 epidemic and demonstrated that molecular tests have high sensitivity and specificity. The current gold standard for SARS-CoV-2 detection is the SARS-CoV-2-specific quantitative RT-PCR test from a nasal and/or pharyngeal swab, sputum or bronchoalveolar lavage.[1,9,22-24] However, if the amount of viral genome in the sample is insufficient or if the correct window period of viral replication is missed, it may give false-negative results.[25] This situation may result in false-negative results due to technical problems in sampling, laboratory practice standards, complex technical procedures and lack of experienced staff. As a result of a systematic review of COVID-19 test accuracy, false-negative rates ranging from 2% to 29% were reported based on the results of patients whose first RT-PCR result was negative and repeat tests were positive.[26]

Due to the low sensitivity of the PCR test in the diagnosis and treatment algorithm of the disease, it is aimed to support the diagnosis and to prevent possible false negativities with thorax CT examination. In a study performed on 1014 patients who underwent thorax CT and RT-PCR tests, the sensitivity of CT was found to be 97% in positive RT-PCR patients.[14] It is thought that CT scanning can help distinguish COVID-19 positive and negative patients in the emergency room.[27-29] Based on this, guidelines were prepared by the WHO for the combined use of thorax CT and RT-PCR in the diagnosis of COVID-19.[27]

Due to the lack of diagnostic reagents, some patients can be clinically diagnosed with thorax CT imaging.[21] Some typical radiological images can be detected by CT in patients with COVID-19 pneumonia. Prominent CT findings of COVID-19 infection are the appearance of prominent ground glass density in bilateral, peripheral and basal regions.[30,31] To date, many descriptive studies and case reports have focused on the CT findings of COVID-19.[1,32-35] However, clinical and laboratory findings of COVID-19 infection are indistinguishable from pneumonia caused by some common respiratory pathogens such as influenza virus, *Streptococcus pneumoniae* and *Mycoplasma pneumoniae*.[36]

Chung et al [34] reported that thorax CT may be negative for viral pneumonia of COVID-19 at the first admission of patients (3/21 patients). Xi et al [37] reported 5/167 (3%) patients with negative RT-PCR for COVID-19 at first admission, despite the thorax CT findings specific to viral pneumonia. In our study, PPV and NPV values of thorax CT in detecting COVID-19 patients were found at low levels such as 48.2% and 72.1%. This situation was thought to be related to the normal tomography images of patients who presented especially in the early period of the disease. Today, with the gradual recognition of the radiological findings of COVID-19 pneumonia, guidelines are prepared for prompt and accurate diagnosis.[38]

Successful management of disease spread will require serological detection of past infection to determine immunity.[39] Antibodies specific to SARS-CoV-2 are usually detected within just more than a week after the onset of symptoms, limiting the role of serology in identifying acute infection.[40] As stated in the literature, it has been shown that IgM and IgG levels can be measured in patients with SARS-CoV-2 infection from the first week of the disease or generally from the second week.[41-43] These findings were found to be parallel to the antibody development characteristics of MERS-CoV infection.[44] This situation restricts the use of antibody tests for screening purposes during the COVID-19 pandemic.[43,45,46]

These limitations have led to the development of different serological microplate ELISA tests.[45,47] Some authors stated that the combination of molecular and serological techniques can reach a sensitivity of 97% in the diagnosis of SARS-CoV-2 infection.[43,45] However, these time-consuming tests based on ELISA are generally not as suitable for clinical use as rapid tests and are difficult to incorporate into management algorithms in emergency departments.[43,45,48,49] Testing IgM and IgG production in response to viral infection can be a simple method to increase the sensitivity and accuracy of the molecular test.[45] Additionally, it can be used for

TABLE 2 Sensitivity levels of Thorax CT findings in patients with positive PCR results

| | | CT finding | | | |
| | | Normal/another diagnosis | COVID-19 | | |
	PCR	n (column %) (row %)	n (column %) (row %)	κ (SE)	P
Clinical management					
Service	Negative	19 (73.1)[npv] (41.3)[sp]	27 (37.0) (58.7)	0.289 (0.089)	.003
	Positive	7 (26.9) (13.2)	46 (63.0)[ppv] (86.8)[ss]		
Intensive care unit	Negative	4 (80.0)[npv] (12.9)[sp]	27 (77.1) (87.1)	0.009 (0.060)	.999
	Positive	1 (20.0) (11.1)	8 (22.9)[ppv] (88.9)[ss]		
Home quarantine	Negative	21 (70.0)[npv] (84.0)[sp]	4 (100.0) (16.0)	−0.195 (0.074)	.314
	Positive	9 (30.0) (100.0)	0 (0.0)[ppv] (0.0)[ss]		
Mechanical ventilator					
No	Negative	41 (70.7)[npv] (48.2)[sp]	44 (46.8) (51.8)	0.219 (0.074)	.004
	Positive	17 (29.3) (25.4)	50 (53.2)[ppv] (74.6)[ss]		
Yes	Negative	3 (100.0)[npv] (17.6)[sp]	14 (77.8) (82.4)	0.075 (0.054)	.589
	Positive	0 (0.0) (0.0)	4 (22.2)[ppv] (100.0)[ss]		
Total	Negative	44 (72.1)[npv] (43.1)[sp]	58 (51.8) (56.9)	0.176 (0.066)	.010
	Positive	17 (27.9) (23.9)	54 (48.2)[ppv] (76.1)[ss]		

Abbreviations: CT, computed tomography; kappa statistical test (Monte Carlo) (κ), kappa coefficient; npv, negative predictive value; ppv, positive predictive value; sp, specificity; ss, sensitivity.

TABLE 3 Sensitivity levels of rapid antibody test in patients with positive PCR results

| | | Rapid antibody test | | | |
| | | Negative | Positive | | |
	PCR	n (column %) (row %)	n (column %) (row %)	κ (SE)	P
Clinical management					
Service	Negative	41 (70.7)[npv] (83.7)[sp]	8 (18.2) (16.3)	0.512 (0.083)	<.001
	Positive	17 (29.3) (32.1)	36 (81.8)[ppv] (67.9)[ss]		
Intensive care unit	Negative	29 (85.3)[npv] (90.6)[sp]	3 (42.9) (9.4)	0.381 (0.177)	.031
	Positive	5 (14.7) (55.6)	4 (57.1)[ppv] (44.4)[ss]		
Home quarantine	Negative	24 (75.0)[npv] (82.8)[sp]	5 (83.3) (17.2)	−0.069 (0.142)	.999
	Positive	8 (25.0) (88.9)	1 (16.7)[ppv] (11.1)[ss]		
Mechanical ventilator					
No	Negative	78 (72.9)[npv] (84.8)[sp]	14 (26.9) (15.2)	0.428 (0.072)	<.001
	Positive	29 (27.1) (43.3)	38 (73.1)[ppv] (56.7)[ss]		
Yes	Negative	16 (94.1)[npv] (88.9)[sp]	2 (40.0) (11.1)	0.582 (0.215)	.022
	Positive	1 (5.9) (25.0)	3 (60.0)[ppv] (75.0)[ss]		
Total	Negative	94 (75.8)[npv] (85.5)[sp]	16 (28.1) (14.5)	0.448 (0.068)	<.001
	Positive	30 (24.2) (42.3)	41 (71.9)[ppv] (57.7)[ss]		

Abbreviations: CT, computed tomography; kappa statistical test (Monte Carlo) (κ), kappa coefficient; npv, negative predictive value; ppv, positive predictive value; sp, specificity; ss, sensitivity.

screening purposes to evaluate antibody profiles in a large population. Large-scale screening programmes using the antibody test are currently carried out by different governments to reveal the percentage of population immunity.

In our study, the sensitivity of the rapid antibody test performed at the first admission of the patients was evaluated. According to our preliminary findings, despite the low sensitivity (57.5%), our having high specificity (85.5%) levels in rapid antibody tests suggests that

the use of rapid antibody test combining with RT-PCR and thorax CT may prevent false-negative results in our society, which population immunity is still low.

There are some limitations in our study. First of all, the selection of patients among the patients who applied to the emergency department made it difficult to evaluate asymptomatic SARS-CoV-2 carriers. It was thought that taking the single NS RT-PCR tests taken at the time of admission as an index caused the false-negative patients to be excluded due to the low sensitivity of the PCR test. In addition, rapid antibody tests evaluated in the emergency department were thought to affect the test results as they could not reach sufficient levels as a result of not allowing the window time required for antibody development.

In conclusion, rapid antibody test and thorax CT examinations were found to have low diagnostic value in patients who applied to the emergency department of our hospital and had a positive first RT-PCR SARS-CoV-2 test. Studies involving larger patient groups are needed for their use alone in diagnosis and screening.

ACKNOWLEDGEMENTS

DISCLOSURE
All authors declare that they have no conflict of interest.

INFORMED CONSENT
Informed consent was obtained from all patients included in the study.

ETHICAL APPROVAL AND HUMAN RIGHTS
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

DATA AVAILABILITY STATEMENT
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Aslı Sener 🔾 https://orcid.org/0000-0002-2107-9438

REFERENCES
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
2. Zhu N, Zhang D, Wang W, et al. A Novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-733.
3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565-574.
4. World Health Organization (WHO). Coronavirus disease 2019 Situation Report 10 30th January 2020. World Heal Organ; 2020.
5. World Health Organization (WHO). Coronavirus disease 2019 Situation Report 51 11th March 2020. World Heal Organ. 2020;2019:2633.
6. Singhal T. A review of coronavirus disease-2019 (COVID-19). *Indian J Pediatr*. 2020;87:281-286.
7. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and pre-symptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility. *Morb Mortal Wkly Rep*. Summ CDC. 2020;69:377-381.
8. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ*. 2020;2:m1375.
9. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25:2000045.
10. Nalla AK, Casto AM, Huang M-LW, et al. Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit. *J Clin Microbiol*. 2020;58:e00557-20.
11. Waggoner JJ, Stittleburg V, Pond R, et al. Triplex real-time RT-PCR for severe acute respiratory syndrome coronavirus 2. *Emerg Infect Dis*. 2020;26:1633-1635.
12. Hogan CA, Sahoo MK, Huang C, et al. Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2020;127:104383.
13. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*. 2020;296:115–117.
14. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology*. 2020;26:200642.
15. Wang X, Yao H, Xu X, et al. Limits of detection of 6 approved RT-PCR kits for the novel SARS-coronavirus-2 (SARS-CoV-2). *Clin Chem*. 2020;66:977-979.
16. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. *J Clin Microbiol*. 2020;58:00760-20.
17. Moran A, Beavis KG, Matushek SM, et al. The detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays. *J Clin Microbiol*. 2020;58:00772-20.
18. Xu Y, Xiao M, Liu X, et al. Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. *Emerg Microbes Infect*. 2020;9:924-927.
19. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*. 2020;92:1518-1524.
20. Weitzel T, Legarraga P, Iruretagoyena M, et al. Head-to-head comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory samples. *bioRxiv*. 2020;2020.05.27.119255. https://doi.org/10.1101/2020.05.27.119255
21. Caruso D, Zerunian M, Polici M, et al. Chest CT features of COVID-19 in Rome, Italy. *Radiology*. 2020;296:79–85.
22. Chan JF-W, Yip CC-Y, To KK-W, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. McAdam AJ, editor. *J Clin Microbiol*. 2020;58:e00310-20.
23. Al-Tawfiq JA, Memish ZA. Diagnosis of SARS-CoV-2 infection based on CT scan vs RT-PCR: reflecting on experience from MERS-CoV. *J Hosp Infect*. 2020;105:154-155.
24. Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets. *Nat Microbiol*. 2020;5:1299–1305.
25. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet*. 2020;395:809-815.

26. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for covid-19: a systematic review. *PLoS One*. 2020;15:0242958.

27. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. *AJR Am J Roentgenol*. 2020;214:1280-1286.

28. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. *Radiology*. 2020;296:15–25.

29. Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. *Radiology*. 2020;158:106-116.

30. Tapé C, Byrd KM, Aung S, Lonks JR, Flanigan TP, Rybak NR. COVID-19 in a patient presenting with syncope and a normal chest X-ray. *R I Med J*. 2020;103:50-51.

31. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update—radiology scientific expert panel. *Radiology*. 2020;296:113–114.

32. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology*. 2020;295:18.

33. Song F, Shi N, Shan F, et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology*. 2020;295:210-217.

34. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). *Radiology*. 2020;295:202-207.

35. Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT Manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology*. 2020;295:208-209.

36. Ai J-W, Zhang H-C, Xu T, et al. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China. *medRxiv*. 2020;2020.02.13.20022673. https://doi.org/10.1101/2020.02.13.20022673

37. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. *Radiology*. 2020;296:41–45.

38. Xu Y-H, Dong J-H, An W-M, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. *J Infect*. 2020;80:394-400.

39. Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. *Emerg Infect Dis*. 2020;26:1478-1488.

40. Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. *Eurosurveillance*. 2020;25:1-6.

41. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19. *J Appl Lab Med*. 2020:5:908-920.

42. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;26:845-848.

43. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis*. 2020;71:2027–2034.

44. Park WB, Perera RAPM, Choe PG, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. *Emerg Infect Dis*. 2015;21:2186-2189.

45. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). *Clin Infect Dis*. 2020;71:778-785.

46. Gao X, Li X. Development of bullous retinal detachment during systemic corticosteroid treatment. *Graefe's Arch Clin Exp Ophthalmol*. 2011;249:1905-1907.

47. Krüttgen A, Cornelissen CG, Dreher M, Hornef M, Imöhl M, Kleines M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. *J Clin Virol*. 2020;128:104394.

48. Jin Y, Wang M, Zuo Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. *Int J Infect Dis*. 2020;94:49-52.

49. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*. 2020;92:1518–1524.